AstraZeneca Reports Top-line Results Of Phase II/III Study Evaluating Recentin
The study, Horizon III, assessed the efficacy of Cediranib compared with Bevacizumab, both in combination with chemotherapy. Clinical activity was observed in the Cediranib arm of the study
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.